Date: 2011-05-31
Type of information:
phase: 1
Announcement: initiation
Company: Boehringer Ingelheim (Germany)
Product: back-up compound from its strategic alliance with Evotec
Action mechanism:
Disease: pain
Therapeutic area: CNS diseases
Country:
Trial details:
Latest
news: Boehringer Ingelheim has advanced a back-up compound from its strategic alliance with Evotec into a Phase I clinical trial. Evotec will receive a milestone payment of € 2.0 million.
The compound was discovered and optimised within a multi-year, multi-target drug discovery collaboration with Boehringer Ingelheim. This alliance has been concluded in 2004 to jointly identify and develop preclinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.